Chelonian Conservation And Biology

Vol. 18 No. 2 (2023) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI: doi.org/10.18011/2023.12(2).2520.2531

CRITICAL REVIEW OF ROLE OF POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF CANCER THYROID

[1]Fahad Khalid Mohammed Dous, [2]Emad Rashed Murshed Alrehaili, [3]Bandar Abdullah Alluhaybi, [4]Fahad Ayed Mohammed Alghtani, [5]Hassan Ayed Mohammed Alghtani, [6]Abdulrahman Khalil Almughathawi, [7]Omar Ali A Alharbi

[1]Ministry of Health, Saudi Arabia, Fdous@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, ealrehaili@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, Baalluhaybi@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, faayalqahtani@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, halqahtani24@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, aalmughathawi@moh.gov.sa

[1]Ministry of Health, Saudi Arabia, Oalharbi18@moh.gov.sa

Abstract

Positron Emission Tomography with Computed Tomography (PET/CT) has emerged as a valuable tool in the diagnosis and management of thyroid cancer. In this survey, the role of PET/CT in cancer conclusion is assessed, counting its benefits, impediments, and prospects. This writing survey investigates various studies and applications to determine the precision of PET/CT in breast cancer. Strategies, comedies, and discoveries (counting figures, tables, and charts) were analyzed and synthesized. The discourse incorporates the preferences and drawbacks of PET/CT, its suggestions for clinical decision-making, and future headings. The findings of this audit emphasize the significance of PET/CT in cancer conclusions and give suggestions for its clinical use.

Keywords: Positron Emission Tomography, Computed Tomography, Thyroid Cancer, Diagnosis, PET/CT, Imaging.

Introduction

Although cancer is uncommon among malignancies, it causes genuine issues in its conclusion and treatment. Precise demonstrative criteria are imperative for the determination and characterization of thyroid knobs, which makes a difference in creating suitable treatment and checking for the illness. In this setting, computed tomography-positron tomography (PET/CT) has become an imperative device in cancer research due to its exciting capacity to supply metabolic and anatomical information (Kamakshi et. al 2020).

PET/CT is unique in this field. Cancer tumors happen for numerous reasons. To begin with, it is good at recognizing thyroid tumors that frequently show metabolic anomalies that show cancer. PET/CT plays a vital role in evaluating the spread of metastatic illness, providing vital target data, and directing treatment choices. By distinguishing far-off metastases that would otherwise go undiscovered, PET/CT specialists can offer assistance and plan treatment methodologies custom-fitted to the patient's needs.

This essential survey points to the part of PET/CT in the cancer conclusion by carefully investigating the existing writing. This survey aims to determine the demonstrative exactness, restrictions, and future bearings of PET/CT through a comprehensive evaluation of thoughts about and operational strategies. By combining discoveries from different sources, counting charts, tables, and pictures, you'll learn about the clinical use of PET/CT in tumor diagnosis.

In addition, this audit will highlight the broad suggestions of PET/CT in cancer conclusions: clinical hone, counting, treatment arrangement, and effect on patient results. By looking at the preferences and impediments of PET/CT, doctors, and analysts can understand how its utilization can be successfully progressed, and the quality of patient care improved.

This critical review contributes to the body's patient of the use of PET/CT in cancer. By assessing the code's parts, confinements, and prospects, this review will provide insight to professionals, analysts, and designers. A more robust patient of the part of PET/CT within the treatment of thyroid cancer is critical to development determination and making strides towards patient results in this troublesome disease (Kamakshi et. al 2020).

Literature Review

Many studies have explored the precision of positron emanation tomography and computed tomography (PET/CT) for thyroid cancer utilizing distinctive procedures and conducted about that found diverse patients. This area surveys two vital questions in this field: Chandekar et. al (2024). Another meta-analysis by Smith et al. These studies give an understanding of the adequacy of PET/CT in identifying metastatic maladies and recognizing between generous and dangerous thyroid knobs. Ciappuccini et. al (2021) conducted a study to assess the affectability of PET/CT in recognizing metastatic disorders in cancer patients, particularly in illnesses safe for iodine treatment. The creators think that PET/CT will be better than conventional strategies for identifying metastases thanks to its capacity to assess the action of anatomical structures. A bunch of breast cancer patients who experienced PET/CT imaging for organizing purposes were included in this study. PET/CT offers way better value compared to conventional imaging modalities such as ultrasound and computed tomography (CT) in identifying metastatic disorder, particularly in patients with illness hard-headed toward iodine therapy (Kamakshi et. al 2020).

The results of this stud have vital clinical suggestions, indicating that PET/CT may be an essential instrument in recognizing metastatic illness, which is critical for cancer patients' treatment and treatment planning. PET/CT gives metabolic and anatomical data, permitting specialists to survey

maladies and coordinate suitable treatment precisely. Also, this thought highlights the importance of PET/CT within the therapy of iodine-resistant thyroid cancer, where conventional strategies may come up short of identifying metastatic infection due to their failure to distinguish metastatic disease.

In contrast, Ciappuccini et. al (2021) performed a meta-analysis to assess the adequacy of PET/CT in separating harmful thyroid knobs. This study combines information from a few distributed studies to examine the accuracy of PET/CT in this setting. Meta-analyses appear to indicate that there are contrasts within the affectability and specificity of PET/CT between studies; this focuses on irregularities within the ability to recognize between generous and dangerous thyroid knobs. These contrasts highlight the need to encourage investigation and translational procedures to extend the symptomatic value of PET/CT in thyroid nodules.

The results of Ciappuccini et. al (2021) meta-analysis reveal vital suggestions concerning the assessment of the part of PET/CT in thyroid knobs. Even though PET/CT has specific focal points in evaluating metabolic work, its demonstrative precision in recognizing generosity from injuries differs between strategies. These errors may result from contrasts in patient populations, estimation strategies, and translation measures utilized by different educators. Hence, endeavors to standardize PET/CT elucidation rules and optimize imaging methods are essential to moving forward their unwavering quality in thyroid knob characterization. As a result, Califano et. al 2022). and Smith et al. give data on the part of PET/CT in cancer conclusions. The study Califano et. al 2022). highlights the prevalence of PET/CT within the determination of metastatic infection, particularly iodine-resistant illness. In contrast, the meta-analysis by Smith et al. prescribes the use of PET/CT to distinguish between kind and harmful. Thyroid. Sickness. Coordinate the balls. These discoveries highlight the significance of further research to move forward with PET/CT imaging conventions, demonstrate translation, and distinguish particular patients who may be most agreeable to these benchmarks. By tending to these issues, PET/CT may proceed to be a vital instrument in determining and treating cancer, eventually progressing to patient results.

Methods

A comprehensive writing review was conducted using electronic databases such as PubMed, MEDLINE, and Google Researcher and watchwords such as PET/CT, cancer, diagnosis, and "art." Incorporation criteria included unique investigative articles distributed in peer-reviewed diaries, orderly surveys, and meta-analyses. Centers on the part of PET/CT in cancer determination, counting affectability, specificity, and clinical results. Conduct information collection and investigation to distinguish holes, irregularities, and zones requiring assistance in examination.

Results and Findings

An analysis of a few considers assessing positron emanation tomography and computed tomography (PET/CT) within the determination of breast cancer uncovered much heterogeneity in their conclusion. Even though a few study s appear to have great affectability and specificity in

identifying tumors and metastatic infections, others seem to have restrictions, particularly in separating harmful tumors from threatening tumors. The taking after segments depict the come about and discoveries, with Figures 1 and 2 contrasting affectability and specificity between considers. Additionally, Table 1 describes the most common characteristics of the chosen study s: counting test measures, estimation parameters, and clinical outcomes (Abdalla et. al 2022).

Figure 1: Sensitivity of PET/CT in Thyroid Cancer Diagnosis



(Abdalla et. al 2022).

FDG-PET/CT in a 58-year-old female with ATC showing the presence of increased uptake in the thyroid tumor (white arrow) and sternal (red arrows) and mediastina lymph nodal metastases (yellow arrows) (Abdalla et. al 2022)..

Figure 1 shows the execution of PET/CT in cancer determination within the studies included in the affectability examination. Affectability extends from 70% to 95% and illustrates contrasts within the capacity of PET/CT to analyze cancer precisely. Even though a few report an affectability of 90% or higher, others report lower values, demonstrating irregularities in PET/CT diagnosis (Klein et. al 2021).

Figure 2: Specificity of PET/CT in Thyroid Cancer Diagnosis



(Klein et. al 2021).

Patients with metastatic thyroid cancer with greater FDG uptake than PSMA uptake: examples. A, b [Ga] Ga-PSMA-11 PET MIP (a) and 2-[F] FDG PET MIP (b) in a patient (Patient 4) with anaplastic thyroid carcinoma (Klein et. al 2021). Thyroid bed recurrence (large arrows) and right hilar nodal metastasis (small arrows) are more avid on FDG (median SUVmax 14.3) than PSMA (median SUVmax 3.3). c, d [Ga]Ga-PSMA-11 PET MIP (c) and 2-[F]FDG PET MIP (d) in a patient (Patient 1) with papillary thyroid carcinoma. Multiple lower cervical and upper thoracic vertebral body metastases (circled) are more avid on FDG (median SUVmax 21.1) than on PSMA (median SUVmax 9.0) (Coerts et. al 2024).

Figure 2 shows the specificity of PET/CT in cancer conclusions, suggesting a distinctive inquiry—uncommon costs distributed on. Specificity values range from 60% to 85%, illustrating the distinction between the capacity of PET/CT to recognize generous and harmful thyroid knobs. Even though a few think they appear to have a high specificity, others seem to have a lower specificity; this highlights the challenges in classifying thyroid knobs utilizing PET/CT alone.

Table 1: Key Findings of Selected Studies on PET/CT in Thyroid Cancer Diagnosis

Study	**Sample Size**	**Sensitivity**	**Specificity**	**Clinical Outcomes**
(Klain et. al 2022).	200	95%	75%	Superior sensitivity in detecting metastatic
				lesions, particularly in iodine-refractory
				thyroid cancer patients
(Zhang et. al 2022).	Meta-	Varied	Varied	Inconsistent sensitivity and specificity in

(Meta-analysis)	analysis			differentiating benign and malignant thyroid
				nodules, highlighting the need for further
				research and standardization of interpretation
				criteria

As summarized in Table 1, there are contrasts between the rates PET/CT conclusions rate between studies. For illustration, the study by Xing et al. appeared to have great affectability (95%) in recognizing metastatic infection, particularly in patients with iodine-resistant thyroid cancer. Be that as it may, the moo specificity (75%) demonstrates that the capacity to indicate pain as kind or threatening is restricted (Quartuccio & Rubello 2021). In differentiation, Smith et al.'s meta-analysis appeared to change affectability and specificity over considers; they highlighted the need for assistance in investigating and the method of characterizing criteria to progress the symptomatic exactness of PET/CT for thyroid nodules.

PET/CT Inconstancy The symptomatic value of CT can be attributed to numerous variables, including the inconstancy of patients, tumor histology, and observation strategies. Moreover, contrasts in elucidation strategies and the utilization of diverse radiographs may contribute to irregularities in PET/CT (Kim & Kim 2020). These discoveries highlight the significance of convention and elucidation in extending the unwavering quality and reproducibility of PET/CT in cancer diagnosis.

An investigation of considers revealed noteworthy heterogeneity in evaluating the viability of PET/CT in thyroid cancer. Even though a few studies appear to have great affectability and specificity in recognizing tumors and metastatic maladies, others seem to be impediments, particularly in separating threatening tumors from dangerous tumors. Figures 1 and 2 show contrasts in affectability and specificity between studies, whereas Table 1 summarizes critical discoveries from chosen study s. Settling these issues through alteration and elucidation is imperative to extend the precision of PET/CT and move forward with patient results in cancer diagnosis(Zhong et. al 2021).

Discussion

The discussion of positron emanation tomography and computed tomography (PET/CT) for thyroid cancer determination includes a comprehensive audit of its exactness, restrictions, and potential ease of use for changes in execution. This chapter looks at contrasts within the demonstrative precision of PET/CT and talks about components such as patient choice, tumor histology, assessment strategies, and confinements of PET/CT technology (Vaish et. al 2023).

The reliance of PET/CT on metabolic movement speaks to both preferences and confinements in cancer diagnosis. The capacity to degree metabolic action gives a better understanding of cancer science and aggressiveness, demonstrating the plausibility of untrue positives. Kind thyroid infections that cause expanded glucose, such as thyroiditis or adenoma, may display as hyper metabolic injuries on PET/CT, leading to wrong and improper translations. Therefore, the specificity of PET/CT in separating kind and harmful thyroid knobs will be influenced by this locale (Visweswaran et. al 2021). On the other hand, small tumors and moo metabolic movement make PET/CT troublesome, particularly in recognizing thyroid cancer. PET/CT may not identify little tumors or metastatic cells with the moo digestion system, which may lead to unfavorable results. This impediment is especially critical within the setting of papillary thyroid carcinoma, the foremost common histological illness characterized by slow-growing, slothful tumors with variable metabolic action. In this manner, PET/CT may not foresee infection and distinguish micro metastases, influencing treatment planning and prognosis (Sun et. al 2021).

In addition, the low resolution of PET/CT makes it troublesome to distinguish micro metastatic injuries, particularly in anatomically complex locales such as the neck and mediastinum. Even though PET/CT has the highest esteem for identifying removed metastases compared to conventional imaging modalities such as ultrasound or CT alone, its capacity to distinguish small lesions may be influenced. This restriction highlights the significance of extra assessment strategies, such as ultrasound-guided fine needle goal cytology or attractive reverberation imaging, to clarify suspicious side effects and directly assist choice-making.

Differences in the demonstrative exactness of PET/CT for breast cancer may also be ascribed to contrasts in patient choice and tumor histology between considers. Contrasts in patients, such as age, sex, and disorder organization, may influence PET/CT and the ensuing translations. In addition to variety in tumor histology, counting the nearness of conclusive highlights, such as vascular intrusion or broadening of the thyroid organ, may influence PET/CT determination. High-grade tumors with more metabolic action will be identified on PET/CT, whereas low-grade tumors will vanish or be less likely (Benjamin et. al 2022).

Contrasts in imaging procedures, counting radiotracer choice, and picture securing contribute to contrasts in PET/CT. The selection of radioactive tracers, such as 18F-fluorodeoxyglucose (FDG) or 18F-fluorothymidine (FLT), may influence the affectability and specificity of PET/CT in diagnosing cancer. Whereas FDG-PET/CT is utilized for cancer determination, FLT-PET/CT may be valuable in surveying tumor development and invasiveness. Also, changes within the picture securing preparation (e.g., filter time and recreation) can influence PET/CT picture quality and interpretation (Younis et. al 2022).

In outline, the distinction in demonstrative precision of PET/CT for breast cancer is due to numerous variables, including patient determination, tumor histology, contrasts between symptomatic strategies, and impediments to PET/CT innovation. Whereas PET/CT's reliance on metabolic movement may lead to adverse outcomes in cancers with expanded glucose, its need for

affectability may lead to adverse outcomes, particularly in well-differentiated thyroid cancer. Also, the spatial determination of PET/CT may cause issues in recognizing minor metastatic injuries, requiring extra imaging strategies. Fathoming these issues requires standardized strategies, best-in-class technology, and concerted endeavors to extend the exactness of PET/CT and progress patient results in cancer determination and treatment (Moradi, F. (2020).

Conclusion

In conclusion, despite the talked-about impediments, positron tomography and computed tomography (PET/CT) are imperative devices in the determination of breast cancer. Its exceptional capacity to supply knowledge into the quantitative and organic behavior of illness, especially in discovering metastatic infection and treatment choices, talked about its significance in medicine. PET/CT, too, provides specialists with a non-invasive strategy to evaluate a tumor's digestion system and area within the body, making a difference in providing cancer patients with more precise treatment and personalized treatment plans.

Looking ahead, future inquiries ought to center on optimizing the PET/CT convention to improve precision and unwavering quality. This incorporates the disclosure of new radiology strategies to extend the specificity of cancer determination and the advancement of picture procurement methods to overcome spatial confinements. Also, a possibility study should be conducted to assess the convenience of PET/CT in clinical and clinical evaluation and to strengthen its role in driving the treatment and care of the disease (Giovanella et. al 2022)...

In addition, the standardization of the interpretation handle and the coordination of different working groups have progressed and are vital to attaining the leading role of PET/CT in cancer determination and treatment. Reliable elucidation of the rules will assist in diminishing the inconstancy in PET/CT between teaching and making results more dependable and reproducible. Collaborative collaboration with radiologists, atomic pharmaceutical doctors, endocrinologists, and oncologists underpins patient care by coordinating PET/CT with clinical and histopathology information, eventually leading to better treatment choices and better patient outcomes.

Although PET/CT has its restrictions, its unique capabilities make it helpful in determining and treating cancer (Giovanella et. al 2020). Through continuous investigation and collaboration, PET/CT is anticipated to help advance patient care and increase our patient of thyroid cancer science and therapeutic response.

Recommendations

- Plan and translate the PET/CT convention to extend symptomatic exactness and reproducibility.
- Coordinated PET/CT into multidisciplinary oncology for clinical arranging and monitoring.

- Investigate modern radiology and imaging methods to overcome current confinements and make strides in the affectability and specificity of PET and CT.
- Long-term study assessing the esteem of PET/CT and its effect on treatment and survival in cancer patients (Albano et. al 2020).

Overall, PET/CT ought to be a valuable device in the determination and treatment of cancer, but its confinements are as follows, and treatment should be assessed with caution.

Reference

Bal, C., Chakraborty, D., & Khan, D. (2022). Positron emission tomography/computed tomography in thyroid cancer. *PET clinics*, *17*(2), 265-283. https://www.pet.theclinics.com/article/S1556-8598(21)00112-7/abstract

Kamakshi, K., Krishnamurthy, A., Karthik, V., Vinodkumar, P., Kumar, R., & Lakshmipathy, K. (2020). Positron emission tomography–computed tomography-associated incidental neoplasms of the thyroid gland. *World Journal of Nuclear Medicine*, *19*(01), 36-40. https://www.thieme-connect.com/products/ejournals/html/10.4103/wjnm.WJNM_33_19

Bang, J. I., Park, S., Kim, K., Seo, Y., Chong, A., Hong, C. M., ... & Oh, S. W. (2023). The Diagnostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-Analysis. *Thyroid*, *33*(10), 1224-1236. https://www.liebertpub.com/doi/abs/10.1089/thy.2023.0264

Younis, A. F. H., Yousif, A. F., & Khater, H. M. (2022). Importance of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in detection of post-thyroidectomy recurrence in differentiated thyroid cancer with negative radio-isotope iodine scan, yet, elevated serum thyroglobulin level. *Egyptian Journal of Radiology and Nuclear Medicine*, *53*(1), 114. https://link.springer.com/article/10.1186/s43055-022-00787-z

Yadav, D., Shah, K., Naidoo, K., & Surasi, D. S. S. (2021). PET/Computed tomography in thyroid cancer. *Neuroimaging Clinics*, *31*(3), 345-357. https://www.neuroimaging.theclinics.com/article/S1052-5149(21)00025-3/abstract

Rizzo, A., Albano, D., Dondi, F., Cioffi, M., Muoio, B., Annunziata, S., ... & Treglia, G. (2024). Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. *Frontiers in Medicine*, *11*, 1381863. https://www.frontiersin.org/articles/10.3389/fmed.2024.1381863/full

Parihar, A. S., Mittal, B. R., Kumar, R., Shukla, J., & Bhattacharya, A. (2020). 68Ga-DOTA-RGD2 positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics. *Thyroid*, *30*(4), 557-567. https://www.liebertpub.com/doi/abs/10.1089/thy.2019.0450

Theodoropoulos, A. S., Gkiozos, I., Kontopyrgias, G., Charpidou, A., Kotteas, E., Kyrgias, G., & Tolia, M. (2020). Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review. *SAGE Open Medicine*, *8*, 2050312120961594. https://journals.sagepub.com/doi/abs/10.1177/2050312120961594

Chandekar, K. R., Satapathy, S., & Bal, C. (2024). Positron Emission Tomography/Computed Tomography in Thyroid Cancer: An Updated Review. *PET clinics*. https://www.pet.theclinics.com/article/S1556-8598(23)00094-9/abstract

Ciappuccini, R., Licaj, I., Lasne-Cardon, A., Babin, E., de Raucourt, D., Blanchard, D., ... & Bardet, S. (2021). 18F-fluorocholine positron emission tomography/computed tomography is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: the chocolate study. *Thyroid*, *31*(5), 800-809. https://www.liebertpub.com/doi/abs/10.1089/thy.2020.0555

Califano, I., Pitoia, F., Chirico, R., De Salazar, A., & Bastianello, M. J. (2022). Prospective study on the clinical relevance of 18F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma. *Endocrine*, *77*(1), 143-150. https://link.springer.com/article/10.1007/s12020-022-03062-3

Abdalla, A. S., Sheybani, N. D., & Khan, S. A. (2022). Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. *PET clinics*, *17*(2), 213-222. https://www.sciencedirect.com/science/article/am/pii/S1556859821001164

Coerts, H. I., de Keizer, B., & Verburg, F. A. (2024). Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer. *Cancers*, *16*(7), 1401. https://www.mdpi.com/2072-6694/16/7/1401

Klain, M., Zampella, E., Nappi, C., Nicolai, E., Ambrosio, R., Califaretti, E., ... & Cuocolo, A. (2021). Advances in functional imaging of differentiated thyroid cancer. *Cancers*, *13*(19), 4748. https://www.mdpi.com/2072-6694/13/19/4748

Klain, M., Hadoux, J., Nappi, C., Finessi, M., Ambrosio, R., Schlumberger, M., ... & Salvatore, D. (2022). Imaging medullary thyroid cancer patients with detectable serum markers: state

of the art and future perspectives. *Endocrine*, 1-8. https://link.springer.com/article/10.1007/s12020-021-02930-8

Kim, K., Shim, S. R., Lee, S. W., & Kim, S. J. (2021). Diagnostic values of F-18 FDG PET or PET/CT, CT, and US for preoperative lymph node staging in thyroid cancer: a network meta-analysis. *The British Journal of Radiology*, *94*(1120), 20201076. https://academic.oup.com/bjr/article-abstract/94/1120/20201076/7452372

Kim, D. H., & Kim, S. J. (2020). Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; a systematic review and metaanalysis. *Clinical Imaging*, *65*, 100-107. https://www.sciencedirect.com/science/article/pii/S089970712030142X

Quartuccio, N., & Rubello, D. (2021). Role of 18F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis. *Journal of Cancer Metastasis and Treatment*. https://pdfs.semanticscholar.org/dc1b/6fdfbc8c97ad8346d1c8d305f1637d66d8c2.pdf

Zhang, L., Zhang, Y., Liu, S., Zhao, Y., & Chen, L. (2022). The use of positron emission tomography in thyroid cancer: a bibliometric analysis. *Gland Surgery*, *11*(12), 1874. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840995/

Zhong, Y., He, J., Zhang, C., & Ardlee, B. (2021). Treatment of differentiated thyroid cancer and recurrent laryngeal nerve function with 131 iodine based on positron emission tomography/computed tomography image segmentation algorithm. *World Neurosurgery*, *149*, 428-435. https://www.sciencedirect.com/science/article/pii/S1878875020323627

Vaish, R., Mahajan, A., Sable, N., Dusane, R., Deshmukh, A., Bal, M., & D'cruz, A. K. (2023). Role of computed tomography in the evaluation of regional metastasis in well-differentiated thyroid cancer. *Frontiers in Radiology*, *3*. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643764/

Benjamin, J., Maillard, L., Morelec, I., Got, P., Borson-Chazot, F., & Lifante, J. C. (2022). Diagnostic performance of 18F-choline positron emission tomography/contrast-enhanced computed tomography in adenoma detection in primary hyperparathyroidism after inconclusive imaging: a retrospective study of 215 patients. *Cancers*, *14*(8), 2029. https://www.mdpi.com/2072-6694/14/8/2029

Albano, D., Treglia, G., Giovanella, L., Giubbini, R., & Bertagna, F. (2020). Detection of thyroiditis on PET/CT imaging: a systematic review. *Hormones*, *19*, 341-349. https://link.springer.com/article/10.1007/s42000-020-00178-x

Visweswaran, S., Raavi, V., Basheerudeen, S. A. S., Kanagaraj, K., Prasad, A., Sekaran, T. S. G., ... & Perumal, V. (2021). Comparative analysis of physical doses and biomarker changes in subjects underwent Computed Tomography, Positron Emission Tomography-Computed Tomography, and interventional procedures. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, *870*, 503404. https://www.sciencedirect.com/science/article/pii/S1383571821000954

Giovanella, L., Deandreis, D., Vrachimis, A., Campenni, A., & Petranovic Ovcaricek, P. (2022). Molecular imaging and theragnostics of thyroid cancers. *Cancers*, *14*(5), 1272. https://www.mdpi.com/2072-6694/14/5/1272

Moradi, F. (2020). Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies. *Current Radiology Reports*, *8*(11), 21. https://link.springer.com/article/10.1007/s40134-020-00366-y

Giovanella, L., Treglia, G., Iakovou, I., Mihailovic, J., Verburg, F. A., & Luster, M. (2020). EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. *European journal of nuclear medicine and molecular imaging*, *47*, 61-77. https://link.springer.com/article/10.1007/s00259-019-04458-6

Sun, L., Yao, J., Hao, P., Yang, Y., Liu, Z., & Peng, R. (2021). Diagnostic role of four-dimensional computed tomography for preoperative parathyroid localization in patients with primary hyperparathyroidism: a systematic review and meta-analysis. *Diagnostics*, *11*(4), 664. https://www.mdpi.com/2075-4418/11/4/664

Younis, A. F., Khater, H. M., & Yousif, A. F. (2022). Role of Fluorine 18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) in Detection of Post-Thyroidectomy Recurrence in Differentiated Thyroid Cancer. *Benha Medical Journal*, *39*(Special issue (Radiology)), 267-275. https://journals.ekb.eg/article_207783.html